Results 21 to 30 of about 580 (130)

Comparing novel treatments in chronic spontaneous urticaria: A critical appraisal of Bruton's tyrosine kinase inhibitors versus anti-cytokine biologics in clinical trials. [PDF]

Clin Transl Allergy
Clinical and Translational Allergy, Volume 15, Issue 4, April 2025.
Diamanti A, Tontini C, Bulfone-Paus S.
europepmc   +2 more sources

Targeting progressive multiple sclerosis: Toward mechanism-informed precision medicine. [PDF]

J Intern Med
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Piehl F, Castelo-Branco G, Jagodic M, Olsson T.   +3 more
europepmc   +2 more sources

BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway. [PDF]

Eur J Immunol
In pDCs, BTK‐inhibition (BTKi) blocks the IFN‐α production via TLR‐9, but not via TLR‐7. Upon TLR‐7 stimulation, BTKi enhances the production of IFN‐α by blocking the inhibitory BDCA‐2 pathway. This might explain partially the failure of BTKi in SLE and is of interest for BTKi trials in multiple sclerosis.
Ceglarek L, Gerhards R, Boldrini V, Wichmann C, Peters A, Meinl E.   +5 more
europepmc   +2 more sources

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

Frontiers in Cell and Developmental Biology, 2021
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target.
H. Yesid Estupiñán, H. Yesid Estupiñán, Anna Berglöf, Rula Zain, Rula Zain, C. I. Edvard Smith   +5 more
doaj   +1 more source

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI [PDF]

Clinical Pharmacology & Therapeutics, 2019
Mechanistic understanding of complex clinical drug–drug interactions (DDIs) with potential involvement of multiple elimination pathways has been challenging, especially given the general lack of specific probe substrates for transporters. Here, we conducted a clinical DDI study to evaluate the interaction potential of fenebrutinib using midazolam (MDZ;
Nicholas S. Jones, Kenta Yoshida, Laurent Salphati, Jane R. Kenny, Matthew R. Durk, Leslie W. Chinn   +5 more
openaire   +2 more sources

What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study

Frontiers in Immunology, 2021
Basophil testing is the most effective single approach for diagnosing type-IIb autoimmune chronic spontaneous urticaria (TIIbaiCSU). A positive basophil test has been linked to long disease duration, higher disease activity, a poor response to ...
João Marcelino, Katrine Baumann, Katrine Baumann, Katrine Baumann, Per Stahl Skov, Per Stahl Skov, Maria Conceição Pereira Santos, Inga Wyroslak, Jörg Scheffel, Jörg Scheffel, Sabine Altrichter, Sabine Altrichter, Anders Woetmann, Anders Woetmann, Manuel Pereira-Barbosa, Célia Costa, Marcus Maurer, Marcus Maurer   +17 more
doaj   +1 more source

Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper. [PDF]

Allergy
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Caramori G, Cari L, Chung KF, Diamant Z, Eguiluz-Gracia I, Knol EF, Jesenak M, Levi-Schaffer F, Nocentini G, O'Mahony L, Palomares O, Redegeld F, Sokolowska M, Van Esch B, Zurlo M, Stellato C.   +20 more
europepmc   +2 more sources

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond. [PDF]

Ann Neurol
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Sabatino JJ, Cree BAC, Hauser SL.
europepmc   +2 more sources

Correction to: Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis [PDF]

Pharmaceutical Research, 2020
The article was published with an incomplete title. The complete title is "Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis" The original article has been corrected.
Phyllis, Chan, Jiajie, Yu, Leslie, Chinn, Marita, Prohn, Jan, Huisman, Brett, Matzuka, William, Hanley, Katie, Tuckwell, Angelica, Quartino   +8 more
openaire   +2 more sources

Paclitaxel biological synthesis promotes the innovation of anti-cancer drugs. [PDF]

Clin Transl Med
Clinical and Translational Medicine, Volume 15, Issue 2, February 2025.
Zhang X, Liu G, Yan J.
europepmc   +2 more sources